A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Last updated:
2026-09-12
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 3 ACTIVE DOSE REGIMENS OF MORF-057 IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE (GARNET)

Intervention/treatment:
MORF-057
Medical condition:
CROHN'S DISEASE
Protocol code:
MORF-057-203
Control number:
281913
Status:
Recruiting
Approved:
January 26, 2024
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT06226883
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 85 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role
CONTACT
Phone:
1-317-615-4559
Name
Physicians interested in becoming principal investigators please contact
Role
CONTACT
Sponsor
MORPHIC THERAPEUTIC, INC.

Locations

CaRe Clinic
Alberta, T4P 1K4
NOT_YET_RECRUITING
Name
Josias Badenhorst
Role
PRINCIPAL_INVESTIGATOR
Phone:
+902 (473) 1499
Clinique IMD
Montreal, H3H 1E8
NOT_YET_RECRUITING
Name
Waqqas Afif
Role
PRINCIPAL_INVESTIGATOR
Diex Recherche Quebec Inc.
Québec, G1V 4T3
RECRUITING
Name
Pascale Chouinard
Role
PRINCIPAL_INVESTIGATOR
Integrated University Health and Social Services Center of Saguenay-Lac-Saint-Jean
Chicoutimi, G7H 5H6
NOT_YET_RECRUITING
Name
Alban Michaud-Herbst
Role
PRINCIPAL_INVESTIGATOR
Phone:
+902 (473) 1499
London Digestive Disease Institute
London, N6K 1M6
NOT_YET_RECRUITING
Name
Waqqas Afif
Role
CONTACT
Phone:
+519 (685) 8500
Name
Vipul Jairath
Role
PRINCIPAL_INVESTIGATOR
London Health Sciences Centre
London, N6A 4L6
RECRUITING
Name
Terry Ponich
Role
PRINCIPAL_INVESTIGATOR
Phone:
+519 (685) 8500
Mount Sinai Hospital
Toronto, M5G 1X5
RECRUITING
Name
Hillary Steinhart
Role
PRINCIPAL_INVESTIGATOR
Nova Scotia Health Authority
Halifax, B3H 1V7
RECRUITING
Name
Kaleb Marr
Role
CONTACT
Phone:
+902 (473) 1499
Name
Jennifer Jones
Role
PRINCIPAL_INVESTIGATOR
Prairie Institute of Liver and Luminal Advanced Research
Lethbridge, T1J 4G9
NOT_YET_RECRUITING
Name
Kaleb Marr
Role
PRINCIPAL_INVESTIGATOR
Scarborough Center for Inflammatory Bowel Disease
Scarborough, M1B 3V4
RECRUITING
Name
Jason Reinglas
Role
PRINCIPAL_INVESTIGATOR
St Joseph'S Health Centre Toronto
Toronto, M6R 1B5
RECRUITING
Name
Ian Bookman
Role
PRINCIPAL_INVESTIGATOR
Toronto Digestive Disease Associates, Inc.
Vaughan, L4L 4Y7
RECRUITING
Name
David Ford
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?

Contacts and resources